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Abstract
Background and Purpose: Although the ‘cromones’ (di-sodium cromoglycate and sodium nedocromil) are used to treat
allergy and asthma, their ‘mast cell stabilising’ mechanism of pharmacological action has never been convincingly
explained. Here, we investigate the hypothesis that these drugs act by stimulating the release of the anti-inflammatory
protein Annexin-A1 (Anx-A1) from mast cells.
Experimental approach: We used biochemical and immuno-neutralisation techniques to investigate the mechanism by
which cromones suppress histamine and eicosanoid release from cord-derived human mast cells (CDMCs) or murine bone
marrow-derived mast cells (BMDMCs) from wild type and Anx-A1 null mice.
Key results: CDMCs activated by IgE-FcRe1 crosslinking, released histamine and prostaglandin (PG) D2, which were inhibited
(30–65%) by 5 min pre-treatment with cromoglycate (10 nM) or nedocromil (10 nM), as well as dexamethasone (2 nM) and
human recombinant Anx-A1 (1–10 nM). In CDMCs cromones potentiated (2–5 fold) protein kinase C (PKC) phosphorylation
and Anx-A1 phosphorylation and secretion (3–5 fold). Incubation of CDMCs with a neutralising anti-Anx-A1 monoclonal
antibody reversed the cromone inhibitory effect. Nedocromil (10 nM) also inhibited (40–60%) the release of mediators
from murine bone marrow derived-mast cells from wild type mice activated by compound 48/80 and IgE-FcRe1 cross-
linking, but were inactive in such cells when these were prepared from Anx-A1 null mice or when the neutralising anti-Anx-
A1 antibody was present.
Conclusions and Implications: We conclude that stimulation of phosphorylation and secretion of Anx-A1 is an important
component of inhibitory cromone actions on mast cells, which could explain their acute pharmacological actions in allergy.
These findings also highlight a new pathway for reducing mediator release from these cells.
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Introduction
Disodium cromoglycate was the first cromone anti-allergic
agent to be discovered but since its introduction into clinical
medicine some 50 years ago [1], other cromones or ‘cromoglycate-
like’ drugs have been developed including nedocromil, lodox-
amide, traxanol and amlexanox. Some H1 antagonists (e.g.
ketotifen, azelastine, pemirolast and olopatidine) also appear to
share a similar pharmacology (or exhibit cross-tachyphylaxis) with
cromoglycate [2]. Most of these drugs are used for the routine
treatment of mild to moderate asthma and/or the topical
treatment of ocular and other allergic symptoms. Cromoglycate
is also used for treating intestinal inflammation [3,4].
The cromoglycate-like drugs can inhibit both the early and the
late phase of the asthmatic reaction in man [5,6] as well as allergic
‘asthma’ or pulmonary inflammation in animal models of the
disease [7–13]. Their anti-asthmatic activity is attributed to their
anti-inflammatory properties by most authorities [14–16].
Although the prototype drug, cromoglycate, was developed in
the 1960s the exact mechanism of action of this group has proved
elusive. Early experiments [1,17–20] led to the concept that these
drugs acted mainly on mast cells to suppress histamine release, but
they also inhibit cytokine generation [21]. The cromones are also
effective in other models of inflammation [22–26] and influence
many facets of the inflammatory process in vivo [27] or in vitro, e.g.
eicosanoid generation [28,29], which are unrelated to mast cell
activation. Any putative mechanism of action must embrace this
diverse pharmacology.
Anx-A1 is a 37kDa member of the annexin super-family (13
proteins in mammals). Both the full length protein and its N-
terminal peptide N-acetyl2-26, have been shown by us, and by
other laboratories to possess powerful anti-inflammatory actions in
a wide variety of animal models of acute and chronic inflammation
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[30] including inhibition of histamine release in allergic pleuritis
[31] and cytokine release in murine models of asthma [32].
Absence or degradation of the protein has also been implicated in
the pathogenesis of asthma and airway hyperactivity [33,34].
Anx-A1 is present in many differentiated cell types in man and
animals but is particularly abundant in cells of the myeloid lineage
including neutrophils, eosinophils, macrophages and mast cells.
Glucocorticoids (GCs) potently stimulate synthesis and secretion
[35–38] of Anx-A1 and there is a correlation between plasma
corticosterone/cortisol and peripheral blood Anx-A1 concentra-
tions [38,39]. Not only do GCs increase the transcription of the
Anx-A1 gene in target cells including mast cells [40] but also
stimulate the release of pre-existing cytosolic pools of Anx-A1
through a receptor-dependent, non-genomic mechanism. This
GC-induced secretory event is preceded by phosphorylation at
Ser27 (and other sites), apparently as a result of PKC activation
[41–43] by a glucocorticoid receptor (GR)-dependent mechanism.
This is crucial for Anx-A1 release as the Ser27-Ala27 mutant cannot
be secreted by cells and has a different intracellular distribution
[44]. Once on the cell surface, Anx-A1 can act in an autocrine (or
paracrine) fashion to inhibit cell activation by interaction with
receptors of the formyl peptide receptor (FPR) family, specifically
FPR-L1, also now known as FPR2 or ALXR in man [45–48].
We have recently reported that the ability of cromones to inhibit
PMN leukocyte activation [49] and eicosanoid release by U937
cells [50] depends upon their ability to release Anx-A1. This is
secondary to a potentiation of PKC activity caused by an
inhibitory action by cromones on the intracellular protein
phosphatase 2A (PP2A), which normally limits the action of PKC.
Here, we report that a similar mechanism also accounts for the
acute inhibitory effect of these drugs on histamine and eicosanoid
secretion by human and murine mast cells. This not only provides
a mechanistic explanation for the acute pharmacological action of
these 50-year-old drugs but also gives a clue to a new pathway
whereby the release of mediators from mast cells can be
modulated.
Methods
Cord-derived human mast cell culture
We used the protocol of Dahl et al [51]. Briefly, commercially
available CD34+ stem cells were cultured for 2 weeks in StemSpan
(StemCell Technologies, Grenoble, France) serum-free medium
supplemented with 100 ng/ml human SCF, 50 ng/ml IL-6 and
1 ng/ml IL-3 (added during the first 14 days) and 100:g/ml
penicillin/streptomycin (Peprotech, London, UK). The medium
was replenished with 10% FCS from week 8.
After 10 weeks, cells were assessed for cytoplasmic granule
appearance using toluidine blue staining, and expression of both
FceRI and c-Kit was assessed by flow cytometry. Culture was
continued until greater than 95% of evaluated cells were identified
as CDMCs and the required cell numbers for experiments were
reached. Cells were used for experiments between 11 and
18 weeks of culture.
Murine bone marrow derived mast cells
To generate BMDMCs, femur bones from Anx-A1+/+ or Anx-
A1-/- BALB/c mice (4-6 weeks old, Charles River, Kent, UK)
were isolated and progenitor cells were flushed out using a sterile
protocol and cultured in RPMI1640 (Invitrogen, Paisley, UK)
containing 10%FBS, 4 mM glutamine, 100 units/ml of penicillin,
100 mg/ml of streptomycin, 0.1 mM non-essential amino acids,
and 50 mM 2-mercaptoethanol together with 5 ng/ml of r-murine
IL-3 and 10 ng/ml SCF (PeproTech, London, UK).
After 4–5 weeks of culture, cells were assessed for cytoplasmic
granule appearance using toluidine blue staining, and expression
of both FceRI and c-Kit was assessed by flow cytometry. Culture
was continued until greater than 95% of evaluated cells were
identified as BMDMCs and the required cell numbers for
experiments were reached.
Animal work was performed according to UK Home Office
regulations (Guidance on the Operation of Animals, Scientific
Procedures Act, 1986) and was approved by the Queen Mary
University of London Ethics Committee (London, UK). Human
cells were prepared according to a protocol approved by the East
London & the City Local Research Ethics Committee (no. 06/
Q605/40; P/00/029 ELCHA, London, UK).
IgE/anti-IgE activation of CDMCs/BMDMCs
Aliquots of CBMCs were activated by crosslinking surface IgE
with an anti-IgE antibody. Cells were incubated overnight with
azide-free IgE (4 mg/mL) to pre-sensitise the cells and the
following day they were activated by adding anti-IgE antibody
(25 mg/mL; Serotec, Oxford, UK). Cell-free supernatants were
taken at 1 h to measure histamine and/or PGD2 release. Aliquots
were stored at –70uC for subsequent analysis.
In the case of BMDMCs, cells were incubated overnight with
anti-mouse monoclonal dinitrophenyl (DNP) - IgE (100 ng/mL;
Sigma) to sensitise the cells and the following day they were
activated by adding DNP-BSA (1 mg/mL; Sigma-Aldrich, Dorset,
UK). Cell-free supernatants were collected at 1h to measure
histamine and/or PGD2 release. Aliquots were stored at –70uC for
subsequent analysis.
When drugs or antibodies were tested, these were added to cells
5 min prior to IgE cross-linking.
48/80 challenge of BMDMCs
Aliquots of BMDMCs were stimulated with Compound 48/80
(10 mg/ml; Sigma-Aldrich, Dorset, UK) for 10 min at 37uC. Drugs
or antibodies were added to the cells 5 min prior to challenge.
Cell-free supernatants were taken to measure histamine and/or
PGD2 release. Aliquots were stored at –70uC for subsequent
analysis.
Drugs used
In previous experiments [50] we noted that glucocorticoids
(GCs) stimulated PKC and Anx-A1 phosphorylation through a
GR-dependant mechanism, and that the known PP2A inhibitor,
okadaic acid, potentiated this effect. For this reason, we included
these drugs alongside the anti-allergics cromoglycate, nedocromil
in our experiments. In one experiment, we also tested ketotifen, a
drug unrelated chemically to the cromone structure, but which
shares some cromone pharmacology [2].
In some cases the drug-treated cell aliquots were incubated with
a well characterised (see; [30]) specific neutralising anti-Anx-A1
(clone 1B; 20 mg/mL), or isotype matched irrelevant (IgG1, ABD
Serotec, Oxford, UK), mabs.
Measurement of histamine release
A commercially-available enzyme immunoassay was used to
detect and quantify histamine-released in the supernatant (SPI bio,
Strasbourg, France). The assay was conducted following the
manufacturer’s protocols. A standard curve ranging from 0.39–
50 nM histamine was prepared using the reagent provided and the
optical density was then read within 60 min in a microplate reader
(TitertekTM, Vienna, Austria) at 405 nm. In some cases, the total
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cell content of histamine was established by freeze-thawing of cells
prior to challenge.
Measurement of PGD2 release
A commercially-available enzyme immunoassay (Cayman
Chemical, Michigan, USA) was used to detect and quantify
PGD2 released in the supernatant. The assay was conducted
following the manufacturer’s protocols. A standard curve ranging
from 78–10,000 pg/ml PGD2 was prepared using the reagent
provided and the optical density was then read within 60 min in a
microplate reader (TitertekTM, Vienna, Austria) at 405 nm.
ELISA for Anx-A1
Anx-A1 protein levels in conditioned medium were determined
by ELISA as reported by Goulding et al [36]. Briefly, 96-well flat-
bottomed ELISA plates (Greiner, Gloucestershire, UK) were
coated with 1 mg anti-Anx-A1 mAb 1B in bicarbonate buffer
(pH 9.6) and incubated overnight at 4uC. After washing in the
bicarbonate buffer, potentially uncoated sites were blocked with
100 mL of PBS containing 1% BSA for 1h at room temperature.
Sample aliquots (100 mL) or Anx-A1 standard solutions (prepared
in 0.1% Tween-20 in PBS; concentration ranging between 10 and
0.001 mg/mL) were added for 1h at 37uC. After extensive washing
in PBS/Tween-20, 100 mL of a polyclonal rabbit anti-human
Anx-A1 serum (Zymed, Invitrogen, Paisley, UK; diluted 1:1000 in
PBS/Tween-20) was added (1h at 37uC) prior to incubation with
donkey anti-rabbit 1gG conjugated to alkaline phosphatase
(1:1000; Sigma). The colour was developed by addition of
100 mL p-nitrophenyl phosphate (1 mg/mL in bicarbonate buffer,
pH 9.6). Absorbance was read at 405nm (with a 620-nm reference
filter) in a microplate reader (TitertekTM, Vienna, Austria). Anx-
A1 levels in the study samples were read against the standard
curve and expressed as ng/ml.
Collection of cellular material for analysis
For assessment of drug effects on protein phosphorylation, test
compounds were pre-incubated for 5 min with aliquots of 26105
CDMCs cultured in 10% FCS medium. To analyse proteins of
interest, CDMCs in suspension following drug treatment, were
decanted into 1.5 ml Eppendorf tubes and gently centrifuged
(2000 RPM) for 5 min. The supernatant was removed and
reserved and the resultant pellet resuspended in 500 ml of lysis
buffer containing 1 mM EDTA (which removes Anx-A1 attached
to the cell membranes), 200 mM NaCl, 20 mM Tris-HCl
(pH 8.0), 1 mM protease and 1 mM phosphatase inhibitors
(equimolar mixture of Na3VO4, b-glycerophosphate, NaF). Both
the cell supernatant and the cell lysate were analysed.
Assessment of Ser27-Anx-A1-P and PKC activation
CDMC extracts were prepared as described above. The total
cellular protein was determined and extracts analysed by
conventional western blotting techniques. Immunodetection was
accomplished using different antibodies recognizing either the full-
length Anx-A1 protein, (polyclonal anti-Anx-A1 antibody; 1:1000,
Invitrogen Ltd, Paisley, UK) or Anx-A1 phosphorylated on Ser27
(polyclonal anti-Ser27-Anx-A1 antibody; 1:1000, Neosystems,
Strasbourg, France).
PKC phosphorylation was assessed using polyclonal anti-
phospho-PKC antibody (1:1000; Cell Signaling Technology;
New England Biolabs UK Ltd, Hitchin, UK). Total PKC was
estimated using a polyclonal pan-specific anti-PKC antibody
(1:1000; Cell Signaling Technology; New England Biolabs UK
Ltd, Hitchin, UK) and a-tubulin using a monoclonal anti-a-
tubulin (1:5000; Sigma-Aldrich, Poole, UK). Activated PKC
isoforms were assessed using a panel of specific anti-phospho
PKC antisera including PKC d (Thr505), PKC o´ Thr538, and PKC
a/b Thr 638/641 antisera (1:1000; Cell Signaling Technology; New
England Biolabs UK Ltd, Hitchin, UK).
A horseradish peroxidase-conjugated secondary antibody
(1:2000; Sigma-Aldrich, Poole, UK) detected bands related to
the proteins of interest and these were revealed by enhanced
chemiluminescence.
Drugs and reagents
Nedocromil sodium was generously supplied by Sanofi-Aventis
(Paris, France) and cromoglycate sodium, dexamethasone phos-
phate, okadaic acid and ketotifen were obtained from Sigma-
Aldrich (Poole, Dorset, UK). The drugs were made freshly on the
day for every experiment. Human recombinant protein Anx-A1
was a gift from our colleague Dr F. D’Acquisto.
Statistical analysis
Unless otherwise stated, In vitro analyses were repeated at least 3
times with distinct mast cell preparations. Values are expressed as
mean 6 SEM of n observations. Statistical differences between the
treated groups were assessed by analysis of variance (ANOVA)
followed by Bonferroni’s test for intergroup comparisons. A
threshold P value # 0.05 was taken as significant.
Results
Effect of cromones, dexamethasone and human
recombinant Anx-A1 on histamine and PGD2 release
from CDMCs
We first established that our cultured and sensitised human
CDMCs responded with a release of histamine and PGD2 when
challenged with IgE/anti-IgE and that this could be inhibited by
the standard cromone, sodium cromoglycate.
Figure 1 (panels A and B) shows that 1h IgE cross-linking in
CDMCs provoked a release of approximately 50% of intracellular
histamine and 800 pg ml-1 PGD2. Cromoglycate produced a
concentration-dependent inhibition of both histamine and PGD2
release with IC50 values of approximately 50 nM and 100 nM
respectively.
We next compared the inhibitory action of the closely-related
cromone, sodium nedocromil and the anti-inflammatory gluco-
corticoid dexamethasone (known to exert many effects through the
release of Anx-A1) on the release of histamine and PGD2 from
IgE/anti-IgE-challenged CDMCs and, since we hypothesise that
these drugs act through the release of endogenous Anx-A1, we
tested the action of human recombinant protein itself.
Figure 1 (panels C and D) shows that both nedocromil (10 nM)
and dexamethasone (2 nM) also blocked histamine (approximately
42% and 29% respectively) and PGD2 (62% and 54% respectively)
release at 5 min. In addition, hr-Anx-A1 at 1 nM and 10 nM
inhibited histamine (approximately 25%, 47% respectively) and
PGD2 release (approximately 63%, 68% respectively) to a similar
extent as these anti-allergic drugs.
As nedocromil had very similar effects to cromoglycate, whilst
being more potent, we chose to use this drug as the main cromone
in subsequent experiments.
Phosphorylation and secretion of Anx-A1 by CDMCs
In our previous work with U937 cells [50] and polymorpho-
nuclear cells [49], we observed that cromones activated PKC and
thereby promoted Anx-A1 phosphorylation. We demonstrated
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that this was an indirect action, probably secondary to inhibition
of PKC de-phosphorylation by PP2A. We therefore checked to see
if incubation with cromones promoted activation of PKC and
phosphorylation and secretion of Anx-A1 from CDMCs in line
with the effects we previously reported.
Figure 2 panel A, shows the effect of escalating concentrations
(0–20 nM) of nedocromil on the amount and disposition of
phospho-PKC and Ser27-phospho Anx-A1 in CDMCs cultured in
StemSpan serum-free medium.
In the untreated lane, small amounts of phospho-PKC and
phospho Anx-A1 are detectable in the cytoplasm as well as in the
media; this is a common finding as these cells are already partly
‘activated’ by the presence of stem cell factor in the medium.
Treatment with nedocromil produces an increase in the amount
of phospho-PKC and phopsho-Anx-A1 in the cell with no further
effect seen beyond 20 nM nedocromil at this time point. In panel
B, nedocromil was used at a concentration of 10 nM and
incubated with the cells for various time points (0–20 min). No
further increase in phospho-PKC or phospho Anx-A1 was seen at
time periods longer than 5 min. These parameters are in line with
other data that we have obtained using (e.g.) U937 cells [50].
The MW of the phosphorylated PKC enzyme detected by
Western blotting using the pan-specific PKC antibody was in the
range 76–82 kDa suggesting the relevant isoform was either PKC
d (78 kDa), PKC h (76 kDa) or PKC a/b (80–82 kDa). When we
probed our blots with a panel of isoform specific anti-phospho
PKC antisera (panel C), no PKC d (Ser643) or PKC h Thr538 was
detectable however, the specific anti- phospho-PKC a/b
Thr638/641 antibody showed good reactivity with a band that
increased following nedocromil treatment. We therefore conclud-
ed that the main kinase responsible for Anx-A1 phosphorylation in
the CDMC system was almost certainly PKCa/b.
Effect of cromones on Anx-A1 secretion
We next determined whether treatment with cromones
provokes Anx-A1 release from CDMCs into the cell medium.
Figure 3 panels A and B show that in addition to nedocromil
(10 nM) itself, cromoglycate (10 nM), ketotifen (10 nM; another
known ‘mast cell stabilising’ drug), dexamethasone (2 nM) and
okadaic acid (10 nM; a known inhibitor of PP2A) potentiate the
activity of PKC and promote additional Anx-A1 phosphorylation.
Panels C and D show a densitometry analysis of 3 similar
experiments and panel E shows that Anx-A1 is secreted into the
cell culture fluid in response to these treatments, as assessed by
ELISA assay.
These results show that all drug treatments tested significantly
increased (,2–5 fold) activated PKC and Ser27 phosphorylated
Figure 1. Cromoglycate, nedocromil, dexamethasone, and human recombinant Anx-A1 inhibit IgE/anti-IgE - induced histamine and
PGD2 release from CDMCs. CDMCs were cultured, sensitised with IgE and challenged with anti-IgE for 1h as described. The cell culture
supernatant was sampled and PGD2 release (pg/ml) or net % release of histamine was assessed by ELISA. Panels A and B. Cromoglycate 0.001–
100 mM produces a concentration-dependent inhibition of histamine (panel A) or PGD2 (panel B) release. Each data point is expressed as the mean6
SEM (n= 3). Panels C and D. Vehicle (control), nedocromil (Ned; 10nM), dexamethasone (Dex; 2nM) or human recombinant Anx-A1 protein (hr-Anx-A1;
1 nM and 10 nM) was added to the wells to test their inhibitory effect on histamine (panel C) and PGD2 release (panel D). Each data point is expressed
as the mean 6 SEM (n = 3).* Signifies P,0.05; **P,0.01 and ***P,0.001 relative to vehicle treated cells.
doi:10.1371/journal.pone.0058963.g001
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Anx-A1 and increased the release of Anx-A1 into the cell culture
fluid by ,3–5 fold above that found under basal conditions.
The acute inhibition of histamine and PGD2 release from
CDMCs by nedocromil is Anx-A1 dependent
To ascertain the role of Anx-A1 in the mechanism of action of
nedocromil, the effect of a specific neutralizing monoclonal anti-
Anx-A1 antibody was tested.
CDMCs were pre-incubated for 20 min with 20 mg/ml
neutralizing Anx-A1, or irrelevant isotype-matched, monoclonal
antibody and then incubated for 5 min with nedocromil sodium
(10 nM). Figure 4 shows the effect of the co-incubation of CDMCs
with neutralising anti-Anx-A1 (or irrelevant) mabs on the effect of
inhibitory action of 10 nM nedocromil on histamine and PGD2
release. Under control conditions, the drug inhibited histamine
and PGD2 release from IgE-activated CDMCs (panel A) as well as
from 48/80-challenged CDMCs (panel B) by approximately 50%
in both cases. This effect was completely abolished in the presence
of the neutralising anti Anx-A1 mab (,6% inhibition). The
irrelevant antibody was inactive. Neither the neutralising nor the
irrelevant antibody alone had any significant effect on the release
of mediators (data not shown).
Effect of cromones on mediators released from BMDMCs
from Anx-A1 wild type and null mice
The above experiments demonstrated that the acute effects of
the cromone nedocromil in human CDMCs appeared to be Anx-
A1 mediated. We next ascertained whether this was solely a
feature of the cultured CDMC model that we used. To test this, we
turned to the use of transgenic mice in which the Anx-A1 gene was
globally deleted. Murine mast cells from wild type and Anx-A1
null mice were cultured and matured as described from bone
marrow precursors.
We first used BMDMCs from wild type mice to establish
whether these behaved in a similar fashion to the human CDMCs.
Figure 4 panel B shows that nedocromil (10 nM) inhibits histamine
(upper bar chart) and PGD2 (lower bar chart) release and that (as
in the case of the CDMCs) this is blocked by immuno-
neutralisation of secreted Anx-A1.
We next tested the inhibitory action of a range of 5
concentrations of nedocromil (0.5 – 10 nM) in two different
protocols where mediator release was stimulated by DNP-IgE/
DNP-BSA cross-linking and stimulation with compound 48/80.
Figure 5 A and B show that nedocromil produces a
concentration-dependent inhibition of histamine and PGD2
release, respectively, from wild type BMDMCs when this is
elicited by either anti-DNP-IgE/DNP-BSA cross-linking in the
case of pre-sensitised cells (panel A, upper bar chart), or compound
48/80 in un-sensitised cells (lower bar chart). However, the drug is
without effect in the cells cultured from Anx-A1 null mice.
We also tested Anx-A1 in the cells lacking the Anx-A1 gene.
Figure 5 (panel C) shows that whilst not being able to release Anx-
A1, these cells retain their sensitivity to the protein which inhibits
histamine and PGD2 release with an IC50 of approximately 5 nM.
Discussion and Conclusions
Our data here clearly indicates that cromones, like the GCs,
promote PKC activation and the subsequent phosphorylation,
externalisation and release of Anx-A1 from CDMCs. The
amounts of Anx-A1 released from CDMCs in this manner yield
Figure 2. Nedocromil activates PKCa/b and promotes Anx-A1 phosphorylation. Panel A. Aliquots of 2610
5 CDMC cells were cultured as
described and incubated for 5 min with vehicle alone or escalating concentrations of nedocromil (Ned; 2-20 nM). The cell medium was then harvested
and the cells lysed. Western blotting was used to assess the intracellular concentration of phospho-PKC and Ser27-phopsho-Anx-A1. A maximum effect
was seen at 5 nM nedocromil at this time point. A representative blot from duplicate experiments. Panel B. Using a similar methodology, the time course
of activation of PKC was assessed using nedocromil (Ned; 10 nM). A maximum effect was seen at 5 min treatment with the drug at this concentration. A
representative blot from duplicate experiments. Panel C. Using samples of lysate prepared from CDMC cells treated with nedocromil (Ned; 5 nM) for
5 min, the relative abundance of three activated isoforms of PKC was assessed using specific antisera. Only PKC a/b was increased by nedocromil
treatment. Activated PKC d or h isoforms were not detected in resting or stimulated cells under these experimental conditions.
doi:10.1371/journal.pone.0058963.g002
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concentrations in the nM range, that are able substantially to
reduce histamine and PGD2 release, as indicated by the
experiments with r-hu-Anx-A1. Our data further suggests that
this process is critical for the acute inhibitory action of the
cromones in CDMCs and also murine mast cells derived from
bone marrow precursors. That this mechanism is common to
several cell types is suggested by our previous observations using
U937 cells [50] and PMN [49], where a similar autocrine Anx-A1
Figure 3. Cromones promote secretion of Anx-A1 from CDMC cells. Panels A and B. Aliquots of 26105 CDMC cells were cultured as described
and incubated for 5 min with vehicle alone (‘control’), nedocromil (Ned; 10 nM), cromoglycate (Crom; 10 nM), ketotifen (Ket; 10 nM), dexamethasone
(Dex; 2 nM) or okadaic acid (Okad; 10 nM). Anx-A1 (panel A) and PKC phosphorylation (panel B) were assessed by western blotting. There is no
detectable change in the absolute intracellular amounts of these proteins at 5 min. Panels D and E. Densitometry data from 3 such experiments was
analysed graphically in the corresponding bar graphs. Panel E. Anx-A1 released into the supernatant after incubation with the drugs was assessed
using an ELISA assay and expressed as ng/ml culture fluid. * Signifies P,0.05; **P,0.01 and ***P,0.001 relative to vehicle treated cells.
doi:10.1371/journal.pone.0058963.g003
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dependent inhibition of cell function was observed following
cromone treatment. We also report that dexamethasone, a
glucocorticoid known to release Anx-A1 using this pathway (see;
[30]), also inhibits histamine and PGD2 release in these cells.
Although not specifically investigated in this study, our previous
work supports the notion that this effect is brought about following
inhibition by these drugs of a phosphatase, probably PP2A, which
secondarily prolongs the activation of PKC thereby further
stimulating Anx-A1 phosphorylation and release.
It has always been clear that the cromones had a unique
mechanism of pharmacological action. Their ‘mast cell stabilising’
effect [1,17–20] is distinct from that of other drugs such as the b-
agonists which, whilst being more efficient at ‘stabilising’ mast cells
[52], do not share the characteristic spectrum of activity of the
cromones.
There are a number of anomalous observations in the cromone
literature that might be explained by the Anx-A1 dependent
mechanism posited here. For example, there is a puzzling
heterogeneity amongst species and between mast cell subtypes,
in the actual ‘stabilising’ effect of these drugs and in the
concentrations required to achieve this effect in vitro [53–55].
Indeed, a recent paper has questioned even whether cromoglycate,
which is highly active in the rat, is active at all in the mouse [56].
This would imply a considerable species-variation in the response
to this drug although we noticed that nedocromil worked well in
our murine BMDMC preparation.
Since these drugs can only exert an appreciable effect on
mediator release if Anx-A1 phosphorylation has already been
triggered by another stimulus, such differences could reflect the
relative degree of activation (and hence PKC stimulation/Anx-A1
phosphorylation) of cells from different sources or subjected to
different experimental protocols. Perhaps this explains why the
cromoglycate drugs have only a variable effect when given in the
absence of an appropriate ‘priming’ stimulus that triggers this
effect. This observation might also explain some of the anomalous
dose-response relationships that have been reported [53,57]. In
this context it is interesting to note that the CDMCs cultured as
described here are partly activated by the presence of SCF and
that there is already a small pool of intracellular Ser27 phospho
Anx-A1 present in these cells even before challenge with antigen
or drug treatment.
The timing of cromone administration relative to the degran-
ulating stimulus is also thought to be crucial to their effect [52] and
these drugs exhibit strong tachyphylaxis [53,58,59]. Indeed, the
refractory response that characteristically follows an application of
these drugs, led to early speculation that the release of a labile
rapidly-depleted anti-inflammatory substance [60] or other
transient intracellular phenomenon [61,62] may be involved in
their action. Our results are consistent with such an interpretation
Figure 4. The inhibitory effect of nedocromil on IgE/anti-IgE-induced histamine and PGD2 release from is Anx-A1 dependent. Panel
A. CDMCs were cultured, sensitised with IgE and challenged with an antigen as described. Nedocromil (Ned; 10 nM) was administered alone or in the
presence of 10 mg/ml neutralising anti-Anx-A1 mab (or an irrelevant control) 5 min before challenge with anti-IgE. Histamine (upper bar chart) and
PGD2 (lower bar chart) release into the cell culture fluid was assessed using ELISA as described above. Panel B. BMDMCs were prepared from wild type
mice as described, and challenged with compound 48/80 as described. Nedocromil (Ned; 10 nM) was administered alone or in the presence of 10 mg/
ml neutralising anti-Anx-A1 mab (or an irrelevant control) 5 min before challenge with anti-IgE. Histamine (top bar chart) and PGD2 (lower bar chart)
release into the cell culture fluid was assessed using ELISA as above. The presence of neither the neutralising, nor the control monoclonal antibody
had any effect on the release of mediators in the absence of nedocromil (data not shown). * Signifies P,0.05 relative to the appropriate control
aliquots.
doi:10.1371/journal.pone.0058963.g004
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and it is likely that the hypothesised ‘anti-inflammatory’ substance
is actually Anx-A1.
Whilst our hypothesis, as presented here, is novel, there have
been several previous observations that link cromone action to
activation of signalling pathways and modification of potential
down-stream molecular targets in mast cells. Treatment of mast
cells with cromoglycate results in the phosphorylation of intracel-
lular protein substrates including the erythrocyte band 4.1 group
protein moesin [61,63] and there have been scattered reports of an
interaction between cromoglycate and PKC stretching back over
some years e.g. [64-66]. Indeed Wang et al [67] previously
investigated the possibility that these drugs inhibited PP2A, but
were unable to detect an effect in their system. Other, earlier,
workers had noted a correlation between the action of these drugs
in vivo in a rat passive cutaneous anaphylaxis model and inhibition
of another, alkaline, phosphatase [68,69].
It is of interest that the anti-allergic drug ketotifen, a non-
cromone member of this group appears to have similar actions on
the Anx-A1 system. Ketotifen is a second-generation H1 antag-
onist that has (in common with some other members of this class)
long been observed to have additional ‘mast cell stabilising
properties’ [2]. It is interesting to speculate that all the H1
antagonists that have this additional action may have a secondary
pharmacology as PP2A inhibitors and that this could be a useful
screen to evaluate this property.
Recently there has been a resurgence of interest in the cromones
and an alternative mechanism of action to that presented in this
study, has been proposed by two groups [70,71] who have
suggested that the cromones may produce their therapeutic actions
by acting through GPR35. This G-protein coupled receptor
signals via the Gi pathway. It is generally thought to be an orphan
receptor although some have suggested that products of trypto-
phan metabolism such as kynurenic acid are the endogenous
ligands, although relatively large concentrations of these substanc-
es are required to activate the receptor.
The first of these studies [71] used (CHO/HEK) cells
transfected with this receptor and demonstrated that cromogly-
cate, nedocromil and zaprinast increased calcium mobilisation and
inositol phosphate accumulation in these cells. There was a
difference in specificity exhibited by the three drugs when tested
on human, mouse and rat GPR35. In terms of potency, all the
drugs were very similar.
Other authors [70] examined human and rat GPR35 in
transfected HEK/yeast cells, using a b-arrestin-2 interaction assay.
They identified a range of ligands including cromoglycate,
zaprinast and dicoumarol. Cromolyn and zaprinast were full
agonists; dicoumarol was a partial agonist.
GPR35 is apparently present in human mast cells (particularly
when treated with IgE) as well as eosinophils and basophils
although its relevance to asthma and allergy or to mast cell
Figure 5. Nedocromil is inactive in BMDMCs from Anx-A1-/- mice. Panel A. BMDMCs were prepared from Anx-A1-/- and wild-type mice as
described. Aliquots were sensitised with anti-DNP-IgE and challenged with DNP-BSA as described (upper graph) or stimulated with 10 mg/ml
compound 48/80 (lower graph). Nedocromil was added in increasing concentrations (0.5 – 10 nM) and the release of histamine into the medium was
assessed by ELISA. Results are expressed as % net histamine release; mean6 SEM; n = 2 with each sample assayed in triplicate. Panel B: BMDMCs were
prepared from Anx-A1-/- and wild-type mice as described. Aliquots were sensitised with anti-DNP-IgE and challenged with DNP-BSA as described
(upper graph) or stimulated with 10 mg/ml compound 48/80 (lower graph). Nedocromil was added in increasing concentrations (1 – 10 nM) and the
release of PGD2 into the medium was assessed by ELISA. Results are expressed as PGD2 released in pg/ml. Panel C. BMDMCs from Anx-A1-/- mice
retain their sensitivity to exogenous Anx-A1. BMDMCs were prepared from Anx-A1-/- and aliquots were sensitised with anti-DNP-IgE and challenged
with DNP-BSA as described, in the presence of escalating concentrations of human recombinant Anx-A1 (0.1–20 nM). Histamine and PGD2 release
into the cell culture fluid was assessed by ELISA. The data is plotted as a concentration-inhibition curve. Each point was the mean of triplicates.
doi:10.1371/journal.pone.0058963.g005
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mediator release is not yet understood so it is unclear how these
actions of the cromones could translate into therapeutic effects - or
how they might integrate with the ‘Anx-A1 dependent’ mecha-
nism we detailed here and elsewhere [49,50]. However, it is worth
noting that the effects that we report here occur within 5 min and
that we have not looked at other actions of the cromones that may
require a longer latency and which perhaps could be mediated by
alternative GPR35 mechanisms.
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